LT2523731T - Antinksčių hormoną modifikuojančio agento panaudojimas - Google Patents

Antinksčių hormoną modifikuojančio agento panaudojimas

Info

Publication number: LT2523731T
Authority: LT; Lithuania
Prior art keywords: modifying agent; adrenal hormone; adrenal; hormone; modifying
Prior art date: 2010-01-14

Application number

LTEP11702096.6T

Other languages

English (en)

Inventor

Qi-Ying Hu

Gary Ksander

Erik Meredith

Lauren G. Monovich

Julien Papillon

Christoph Schumacher

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-01-14

Filing date

2011-01-13

Publication date

2019-02-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43735742&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2523731(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-01-13 Application filed by Novartis Ag filed Critical Novartis Ag

2019-02-11 Publication of LT2523731T publication Critical patent/LT2523731T/lt

Links

230000001919 adrenal effect Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Steroid Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

LTEP11702096.6T 2010-01-14 2011-01-13 Antinksčių hormoną modifikuojančio agento panaudojimas LT2523731T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US29498010P	2010-01-14	2010-01-14
PCT/US2011/021100 WO2011088188A1 (en)	2010-01-14	2011-01-13	Use of an adrenal hormone-modifying agent

Publications (1)

Publication Number	Publication Date
LT2523731T true LT2523731T (lt)	2019-02-11

Family

ID=43735742

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTEP11702096.6T LT2523731T (lt)	2010-01-14	2011-01-13	Antinksčių hormoną modifikuojančio agento panaudojimas
LTPA2020512C LTC2523731I2 (lt)	2010-01-14	2020-06-19	Antinksčių hormoną modifikuojančio agento panaudojimas

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
LTPA2020512C LTC2523731I2 (lt)	2010-01-14	2020-06-19	Antinksčių hormoną modifikuojančio agento panaudojimas

Country Status (33)

Country	Link
US (2)	US8609862B2 (lt)
EP (2)	EP3527208A1 (lt)
JP (4)	JP5602250B2 (lt)
KR (1)	KR101412206B1 (lt)
CN (2)	CN102711916B (lt)
AU (1)	AU2011205290C1 (lt)
BR (1)	BR112012017458B1 (lt)
CA (1)	CA2786443C (lt)
CL (1)	CL2012001961A1 (lt)
CY (2)	CY1121320T1 (lt)
DK (1)	DK2523731T3 (lt)
ES (1)	ES2707596T3 (lt)
HR (1)	HRP20190064T1 (lt)
HU (2)	HUE041967T2 (lt)
IL (1)	IL220804A0 (lt)
LT (2)	LT2523731T (lt)
LU (1)	LUC00159I2 (lt)
MA (1)	MA33904B1 (lt)
ME (1)	ME03371B (lt)
MX (2)	MX2012008212A (lt)
NL (1)	NL301043I2 (lt)
NO (1)	NO2020012I1 (lt)
NZ (1)	NZ601077A (lt)
PH (1)	PH12012501422B1 (lt)
PL (1)	PL2523731T3 (lt)
PT (1)	PT2523731T (lt)
RS (1)	RS58234B1 (lt)
SG (1)	SG182393A1 (lt)
SI (1)	SI2523731T1 (lt)
TN (1)	TN2012000352A1 (lt)
TR (1)	TR201900515T4 (lt)
WO (1)	WO2011088188A1 (lt)
ZA (1)	ZA201205058B (lt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2011205290C1 (en) *	2010-01-14	2014-11-06	Recordati Ag	Use of an adrenal hormone-modifying agent
JP2013528658A (ja)	2010-06-16	2013-07-11	エンベラニューロセラピューティクス，インコーポレイティド	依存、精神疾患、及び神経変性病の治療のための組成物と方法
AR086665A1 (es)	2011-06-14	2014-01-15	Lilly Co Eli	Inhibidor de aldosterona sintasa y composiciones farmaceuticas
US20140235667A1 (en)	2011-09-22	2014-08-21	Merck Sharp & Dohme Corp.	Imidazopyridyl compounds as aldosterone synthase inhibitors
US9193724B2 (en)	2011-09-22	2015-11-24	Merck Sharp & Dohme Corp.	Triazolopyridyl compounds as aldosterone synthase inhibitors
WO2013043521A1 (en)	2011-09-22	2013-03-28	Merck Sharp & Dohme Corp.	Pyrazolopyridyl compounds as aldosterone synthase inhibitors
IN2014DN06781A (lt) *	2012-01-17	2015-05-22	Novartis Ag
AU2013246908B2 (en) *	2012-04-12	2016-06-30	Novartis Ag	Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors
EP2903615B1 (en)	2012-10-05	2021-04-07	Merck Sharp & Dohme Corp.	5-pyridin-3-yl-2,3-dihydro-1h-indole derivatives as aldosterone synthase (cyp11b2) inhibitors for the treatment of hypertension
JP2015093832A (ja) *	2013-11-08	2015-05-18	日本メジフィジックス株式会社	放射性ハロゲン標識化合物又はその塩、これを含む医薬
SI3166596T1 (sl) *	2014-07-07	2018-10-30	Novartis Ag	Farmacevtske odmerne oblike
WO2016048984A1 (en) *	2014-09-25	2016-03-31	Cortendo Ab (Publ)	Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole
HUE054248T2 (hu)	2015-01-29	2021-08-30	Recordati Ag	Eljárás kondenzált imidazo-származékok elõállítására
US20160287565A1 (en)	2015-04-06	2016-10-06	Millendo Therapeutics, Inc.	Combination therapy for treating disorders associated with excess cortisol production
US20180185375A1 (en) *	2015-06-22	2018-07-05	Embera Neurotherapeutics, Inc.	Compositions and methods for the treatment of substance use disorders, addiction, and psychiatric disorders
WO2018165649A1 (en)	2017-03-10	2018-09-13	Embera Neurotherapeutics, Inc.	Pharmaceutical compositions and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4889861A (en) *	1982-12-21	1989-12-26	Ciba-Geigy Corp.	Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4814333A (en)	1987-07-28	1989-03-21	The Trustees Of Dartmouth College	Method for treatment of hypercortisolemic, depressed patients
US5503843A (en)	1994-04-22	1996-04-02	Flora Inc.	Transdermal delivery of alpha adrenoceptor blocking agents
US5658881A (en)	1994-10-14	1997-08-19	Twk, Inc.	Method for topical inhibition of the metabolic activity of cytochrome P450
DE19814087A1 (de) *	1998-03-30	1999-10-14	Lohmann Therapie Syst Lts	Feuchtigkeitsaktivierbares therapeutisches System
ATE457169T1 (de)	1998-10-15	2010-02-15	Imp Innovations Ltd	Verbindungen für die behandlung von gewichtsverlust
ES2275853T3 (es) *	2001-02-16	2007-06-16	Aventis Pharmaceuticals Inc.	Derivados heterociclicos de urea y su uso como ligandos de receptores de dopamina d3.
TWI263640B (en)	2001-12-19	2006-10-11	Bristol Myers Squibb Co	Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
GB0212412D0 (en) *	2002-05-29	2002-07-10	Novartis Ag	Combination of organic compounds
JP5138875B2 (ja)	2005-07-19	2013-02-06	株式会社デンソー	センサ装置
GT200600381A (es) *	2005-08-25	2007-03-28		Compuestos organicos
TW200804378A (en)	2005-12-09	2008-01-16	Speedel Experimenta Ag	Organic compounds
EP2007206A4 (en)	2006-03-16	2010-12-08	Yeda Res & Dev	METHOD AND COMPOSITION FOR THE PROTECTION OF NEURONAL TISSUE FROM DEGATES INDUCED BY HIGH LEVELS OF GLUTAMATE
RU2008150752A (ru) *	2006-05-26	2010-07-10	Новартис АГ (CH)	Ингибиторы альдостеронсинтазы и/или 11-гидроксилазы
EP1886695A1 (en)	2006-06-27	2008-02-13	Speedel Experimenta AG	Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
KR20090055595A (ko) *	2006-08-25	2009-06-02	노파르티스 아게	알도스테론 신타제 및/또는 11-베타-히드록실라제 및/또는 아로마타제에 의해 매개된 장애의 치료를 위한 융합 이미다졸 유도체
EA200900812A1 (ru) *	2006-12-18	2009-12-30	Новартис Аг	Производные 4-имидазолил-1,2,3,4-тетрагидрохинолина и их применение в качестве ингибиторов альдостерон/11-бета-гидроксилазы
EP2095819A1 (en) *	2008-02-28	2009-09-02	Maastricht University	N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors
AR072297A1 (es)	2008-06-27	2010-08-18	Novartis Ag	Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
AU2011205290C1 (en) *	2010-01-14	2014-11-06	Recordati Ag	Use of an adrenal hormone-modifying agent
IN2014DN06781A (lt) *	2012-01-17	2015-05-22	Novartis Ag
AU2013246908B2 (en) *	2012-04-12	2016-06-30	Novartis Ag	Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors

2011
- 2011-01-13 AU AU2011205290A patent/AU2011205290C1/en active Active
- 2011-01-13 MA MA35039A patent/MA33904B1/fr unknown
- 2011-01-13 LT LTEP11702096.6T patent/LT2523731T/lt unknown
- 2011-01-13 CN CN201180006082.5A patent/CN102711916B/zh active Active
- 2011-01-13 HR HRP20190064TT patent/HRP20190064T1/hr unknown
- 2011-01-13 DK DK11702096.6T patent/DK2523731T3/en active
- 2011-01-13 CN CN201510632085.XA patent/CN105440038A/zh active Pending
- 2011-01-13 BR BR112012017458-4A patent/BR112012017458B1/pt active IP Right Grant
- 2011-01-13 PT PT11702096T patent/PT2523731T/pt unknown
- 2011-01-13 CA CA2786443A patent/CA2786443C/en active Active
- 2011-01-13 PL PL11702096T patent/PL2523731T3/pl unknown
- 2011-01-13 WO PCT/US2011/021100 patent/WO2011088188A1/en not_active Ceased
- 2011-01-13 US US13/521,548 patent/US8609862B2/en active Active
- 2011-01-13 HU HUE11702096A patent/HUE041967T2/hu unknown
- 2011-01-13 MX MX2012008212A patent/MX2012008212A/es active IP Right Grant
- 2011-01-13 NZ NZ601077A patent/NZ601077A/en unknown
- 2011-01-13 EP EP18201925.7A patent/EP3527208A1/en not_active Withdrawn
- 2011-01-13 MX MX2014011700A patent/MX354022B/es unknown
- 2011-01-13 TR TR2019/00515T patent/TR201900515T4/tr unknown
- 2011-01-13 RS RS20190043A patent/RS58234B1/sr unknown
- 2011-01-13 ES ES11702096T patent/ES2707596T3/es active Active
- 2011-01-13 SI SI201131654T patent/SI2523731T1/sl unknown
- 2011-01-13 EP EP11702096.6A patent/EP2523731B1/en active Active
- 2011-01-13 SG SG2012049995A patent/SG182393A1/en unknown
- 2011-01-13 JP JP2012549066A patent/JP5602250B2/ja active Active
- 2011-01-13 KR KR1020127021180A patent/KR101412206B1/ko active Active
- 2011-01-13 PH PH1/2012/501422A patent/PH12012501422B1/en unknown
- 2011-01-13 ME MEP-2019-8A patent/ME03371B/me unknown
2012
- 2012-07-05 IL IL220804A patent/IL220804A0/en active IP Right Grant
- 2012-07-06 ZA ZA2012/05058A patent/ZA201205058B/en unknown
- 2012-07-06 TN TNP2012000352A patent/TN2012000352A1/en unknown
- 2012-07-13 CL CL2012001961A patent/CL2012001961A1/es unknown
2013
- 2013-11-13 US US14/079,018 patent/US9434754B2/en active Active
2014
- 2014-07-04 JP JP2014139066A patent/JP6181610B2/ja active Active
2016
- 2016-07-14 JP JP2016139449A patent/JP6425688B2/ja active Active
2018
- 2018-05-01 JP JP2018087986A patent/JP2018150326A/ja active Pending
2019
- 2019-01-24 CY CY20191100096T patent/CY1121320T1/el unknown
2020
- 2020-06-09 NO NO2020012C patent/NO2020012I1/no unknown
- 2020-06-10 NL NL301043C patent/NL301043I2/nl unknown
- 2020-06-16 LU LU00159C patent/LUC00159I2/fr unknown
- 2020-06-19 LT LTPA2020512C patent/LTC2523731I2/lt unknown
- 2020-06-23 HU HUS2000018C patent/HUS000508I2/hu unknown
- 2020-07-08 CY CY2020018C patent/CY2020018I1/el unknown

Also Published As

Publication number	Publication date
NL301043I2 (nl)	2020-07-06
BR112012017458A2 (pt)	2017-12-19
JP2018150326A (ja)	2018-09-27
KR101412206B1 (ko)	2014-06-25
HUE041967T2 (hu)	2019-06-28
TR201900515T4 (tr)	2019-02-21
JP6425688B2 (ja)	2018-11-21
EP2523731B1 (en)	2018-10-24
PH12012501422A1 (en)	2012-10-22
TN2012000352A1 (en)	2014-01-30
JP2015013859A (ja)	2015-01-22
KR20120116482A (ko)	2012-10-22
PT2523731T (pt)	2019-01-21
PH12012501422B1 (en)	2018-09-12
RU2012134510A (ru)	2014-02-20
US20140171392A1 (en)	2014-06-19
CA2786443A1 (en)	2011-07-21
LTPA2020512I1 (lt)	2020-07-27
US9434754B2 (en)	2016-09-06
CL2012001961A1 (es)	2013-03-22
EP3527208A1 (en)	2019-08-21
MA33904B1 (fr)	2013-01-02
PL2523731T3 (pl)	2019-04-30
NZ601077A (en)	2014-07-25
LTC2523731I2 (lt)	2022-05-10
SG182393A1 (en)	2012-08-30
CN102711916A (zh)	2012-10-03
US20120295888A1 (en)	2012-11-22
CN102711916B (zh)	2015-09-02
NL301043I1 (nl)	2020-06-17
JP6181610B2 (ja)	2017-08-16
AU2011205290B2 (en)	2014-06-26
RS58234B1 (sr)	2019-03-29
CY2020018I2 (el)	2020-11-25
HRP20190064T1 (hr)	2019-03-08
DK2523731T3 (en)	2019-02-04
AU2011205290C1 (en)	2014-11-06
EP2523731A1 (en)	2012-11-21
CY2020018I1 (el)	2020-11-25
IL220804A0 (en)	2012-08-30
JP5602250B2 (ja)	2014-10-08
CY1121320T1 (el)	2020-05-29
JP2013517280A (ja)	2013-05-16
CA2786443C (en)	2018-12-11
AU2011205290A1 (en)	2012-08-02
ME03371B (me)	2020-01-20
HUS2000018I1 (hu)	2020-07-28
ES2707596T3 (es)	2019-04-04
MX354022B (es)	2018-02-08
RU2598708C2 (ru)	2016-09-27
ZA201205058B (en)	2014-04-30
CN105440038A (zh)	2016-03-30
LUC00159I1 (lt)	2020-06-16
LUC00159I2 (lt)	2021-07-06
WO2011088188A1 (en)	2011-07-21
BR112012017458B1 (pt)	2020-10-20
US8609862B2 (en)	2013-12-17
MX2012008212A (es)	2012-08-03
NO2020012I1 (no)	2020-06-09
SI2523731T1 (sl)	2019-02-28
HUS000508I2 (hu)	2021-03-29
JP2017002063A (ja)	2017-01-05

Publication	Publication Date	Title
HUS2000018I1 (hu)	2020-07-28	Mellékvese hormon-módosító szer alkalmazása
IL255252A0 (en)	2017-12-31	Production of pipes
IL222227A0 (en)	2012-12-31	Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use
IL237581B (en)	2018-11-29	Derivatives of 6-oxo-pyrazinopyrrolopyrimidines
EP2566328A4 (en)	2013-10-16	indazoles
SG10201506840QA (en)	2015-10-29	Cytotoxicity-inducing therapeutic agent
GB201003274D0 (en)	2010-04-14	Methods of connecting
ZA201206456B (en)	2013-05-29	Uses of dgati inhibitors
IL224340A (en)	2015-10-29	Sanitary cause
IL220850A0 (en)	2012-09-24	Pigmentation-preventing or-ameliorating agent
ZA201302952B (en)	2014-10-29	Fungicidal compositions and methods of use
PL2363354T3 (pl)	2013-05-31	Dozownik substancji czynnej
GB201009603D0 (en)	2010-07-21	Anti-inflammatory agent
GB201009342D0 (en)	2010-07-21	Use of steroid compounds
HU1000688D0 (en)	2011-02-28	Use of trifluoro-phal
GB2480497B (en)	2012-05-16	Locating structure of handcart
TWM390349U (en)	2010-10-11	Structure of door-in-door
TWM386865U (en)	2010-08-21	Residue-filtering structure of juice-extractor
GB201018597D0 (en)	2010-12-22	Inhibitors
PL391723A1 (pl)	2012-01-16	Środek zwilżający
PL391725A1 (pl)	2012-01-16	Środek zwilżający
PL392666A1 (pl)	2012-04-23	Środek gaśniczy
TWM388315U (en)	2010-09-11	Improved structure of hemoclip
TWM400763U (en)	2011-04-01	Improved structure of cold-accumulating cravats
GB201003727D0 (en)	2010-04-21	Therapeutic agent